Sensei Biotherapeutics (NASDAQ:SNSE) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a report released on Friday morning, Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.

Separately, Stephens reissued an overweight rating and set a $5.00 price target on shares of Sensei Biotherapeutics in a research report on Friday.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ SNSE traded down $0.66 during mid-day trading on Friday, reaching $0.79. 1,408,115 shares of the company’s stock traded hands, compared to its average volume of 466,501. The business has a 50-day simple moving average of $1.21 and a 200 day simple moving average of $0.92. Sensei Biotherapeutics has a 1-year low of $0.51 and a 1-year high of $1.94. The company has a quick ratio of 12.07, a current ratio of 12.07 and a debt-to-equity ratio of 0.01.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03). As a group, sell-side analysts anticipate that Sensei Biotherapeutics will post -1.07 EPS for the current fiscal year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.